Aims To estimate the health utilities and quality-adjusted life years (QALYs) in patients with
amyotrophic lateral sclerosis (ALS) receiving reldesemtiv versus placebo in FORTITUDE …

Background Amyotrophic lateral sclerosis (ALS) is a devastating disease which leads to loss
of muscle function and paralysis. Historically, clinical drug development has been …

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease typically causing death
within three years. Understanding the impact of disease on patients using health utility at …

Abstract Background The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised
(ALSFRS-R) is the preferred measure of health outcome in clinical trials in motor neuron …

Objectives Reexamine cost-effectiveness of riluzole in the treatment of amyotrophic lateral
sclerosis (ALS) in light of recent advances in disease staging and understanding of stage …

Amyotrophic lateral sclerosis (ALS) is a difficult to diagnose, fatal, progressive degenerative
disease with an average survival time of 2 to 5 years. Percutaneous endoscopic gastrotomy …

This study reports the results of a long-term economic evaluation of riluzole in the treatment
of amyotrophic lateral sclerosis (ALS) versus best supportive care in the United Kingdom …

We conducted a cost-benefit analysis of riluzole therapy in patients with amyotrophic lateral
sclerosis (ALS; motor neuron disease; Lou Gehrig's disease). The survival of patients with …

Objectives This study assessed the feasibility of using the Milano-Torino staging (MiToS)
system for conducting economic evaluation to measure health outcomes in amyotrophic …

Objective: In patients with amyotrophic lateral sclerosis, long term treatment with riluzole has
been reported to improve survival or tracheostomy-free survival in comparison with placebo …